Aclarion provides corporate update highlighting market expansion as clarity trial advances toward key data catalyst

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across u.s., u.k., and e.u.
ACON Ratings Summary
ACON Quant Ranking